These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
509 related articles for article (PubMed ID: 34010616)
1. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Koo BK; Kang J; Park KW; Rhee TM; Yang HM; Won KB; Rha SW; Bae JW; Lee NH; Hur SH; Yoon J; Park TH; Kim BS; Lim SW; Cho YH; Jeon DW; Kim SH; Han JK; Shin ES; Kim HS; Lancet; 2021 Jun; 397(10293):2487-2496. PubMed ID: 34010616 [TBL] [Abstract][Full Text] [Related]
2. Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial. Rhee TM; Bae JW; Park KW; Rha SW; Kang J; Lee H; Yang HM; Kwak SH; Chae IH; Shin WY; Kim DK; Oh JH; Jeong MH; Kim YH; Lee NH; Hur SH; Yoon J; Han JK; Shin ES; Koo BK; Kim HS; JAMA Cardiol; 2023 Jun; 8(6):535-544. PubMed ID: 37043192 [TBL] [Abstract][Full Text] [Related]
3. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. Kang J; Park KW; Lee H; Hwang D; Yang HM; Rha SW; Bae JW; Lee NH; Hur SH; Han JK; Shin ES; Koo BK; Kim HS Circulation; 2023 Jan; 147(2):108-117. PubMed ID: 36342475 [TBL] [Abstract][Full Text] [Related]
4. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S; Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073 [TBL] [Abstract][Full Text] [Related]
5. Association of Clinical Outcomes With Sex in Patients Receiving Chronic Maintenance Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Post Hoc Gender Analysis of the HOST-EXAM Study. Shin ES; Jun EJ; Kim B; Won KB; Koo BK; Kang J; Park KW; Rhee TM; Yang HM; Han JK; Kim HS; J Am Heart Assoc; 2023 Apr; 12(8):e026770. PubMed ID: 37042284 [TBL] [Abstract][Full Text] [Related]
6. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC; Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699 [TBL] [Abstract][Full Text] [Related]
7. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL; Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220 [TBL] [Abstract][Full Text] [Related]
8. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Kim CJ; Park MW; Kim MC; Choo EH; Hwang BH; Lee KY; Choi YS; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Seung KB; Jeong MH; Yim HW; Ahn Y; Chang K; Lancet; 2021 Oct; 398(10308):1305-1316. PubMed ID: 34627490 [TBL] [Abstract][Full Text] [Related]
9. A retrospective study of the safety and efficacy of clopidogrel versus aspirin monotherapy one year after coronary stent implantation. Lan K; Gao H; Gong H BMC Pharmacol Toxicol; 2024 Sep; 25(1):67. PubMed ID: 39334336 [TBL] [Abstract][Full Text] [Related]
10. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial. Lee H; Koo BK; Park KW; Shin ES; Lim SW; Rha SW; Bae JW; Jeon DW; Oh SK; Hur SH; Kim BS; Lee JH; Park TH; Lee NH; Kim HS; Am Heart J; 2017 Mar; 185():17-25. PubMed ID: 28267471 [TBL] [Abstract][Full Text] [Related]
11. Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial. Li Y; Li J; Wang B; Jing Q; Zeng Y; Hou A; Wang Z; Liu A; Zhang J; Zhang Y; Zhang P; Jiang D; Liu B; Fan J; Zhang J; Li L; Su G; Yang M; Jiang W; Qu P; Zeng H; Li L; Qiu M; Ru L; Chen S; Zhou Y; Qiao S; Stone GW; Angiolillo DJ; Han Y; JAMA Cardiol; 2024 Jun; 9(6):523-531. PubMed ID: 38630489 [TBL] [Abstract][Full Text] [Related]
12. Clopidogrel Versus Aspirin as Chronic Maintenance Antiplatelet Monotherapy in Patients After Percutaneous Coronary Intervention With Chronic Kidney Disease: A Post Hoc Analysis of the HOST-EXAM Trial. Kang J; Park SH; Park KW; Koo BK; Lee H; Han M; Hwang D; Yang HM; Chae IH; Shin WY; Oh JH; Kim YH; Park TH; Kim BS; Han JK; Shin ES; Kim HS J Am Heart Assoc; 2024 Sep; 13(18):e035269. PubMed ID: 39248265 [TBL] [Abstract][Full Text] [Related]
13. Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial. Lee CH; Lee JY; Park GM; Lee SW; Kim HS; Choi YJ; Nam CW; Cho JH; Shin WY; Seo JB; Choi SW; Lee JH; Min PK; Her SH; Lee PH; Ahn JM; Park DW; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ Am J Cardiol; 2018 Feb; 121(4):423-429. PubMed ID: 29273207 [TBL] [Abstract][Full Text] [Related]
14. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Toyoda K; Uchiyama S; Yamaguchi T; Easton JD; Kimura K; Hoshino H; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K; Lancet Neurol; 2019 Jun; 18(6):539-548. PubMed ID: 31122494 [TBL] [Abstract][Full Text] [Related]
15. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645 [TBL] [Abstract][Full Text] [Related]
16. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial. Hong SJ; Lee SJ; Suh Y; Yun KH; Kang TS; Shin S; Kwon SW; Lee JW; Cho DK; Park JK; Bae JW; Kang WC; Kim S; Lee YJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK; Circulation; 2024 Feb; 149(8):562-573. PubMed ID: 37878786 [TBL] [Abstract][Full Text] [Related]
17. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S; Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078 [TBL] [Abstract][Full Text] [Related]
18. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW; Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163 [TBL] [Abstract][Full Text] [Related]
19. Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial. Lee YJ; Cho JY; Yun KH; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS EuroIntervention; 2022 Aug; 18(6):471-481. PubMed ID: 35470799 [TBL] [Abstract][Full Text] [Related]
20. Impact of Age on Antiplatelet Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: A Post Hoc Analysis From the HOST-EXAM Extended Study. Lee K; Kang J; Park KW; Park TH; Kim BS; Lim SW; Cho YH; Jeon DW; Kim SH; Yang HM; Kang HJ; Han JK; Shin ES; Koo BK; Kim HS Can J Cardiol; 2024 Jan; 40(1):43-52. PubMed ID: 37742741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]